Bio Sequence

Biological Glossary | What is Attenuator?

27 October 2023
3 min read

Attenuator in biotechnology refers to a nucleotide sequence in DNA that can lead to premature termination of transcription, a process found in bacteria and archaea. This mechanism, known as attenuation, involves a provisional stop signal in the DNA segment that corresponds to the leader sequence of mRNA, leading to a stall in the ribosome in the attenuator region in the mRNA leader. Depending on metabolic conditions, the attenuator either stops transcription or allows read-through to the mRNA's structural gene part and synthesis of the appropriate protein. This mechanism provides sensitive and fast regulation of gene operons, usually repressing genes in the presence of their product or a downstream metabolite. Attenuators are classified based on the type of molecule that induces the change in RNA structure.

Free registration is available for the Bio biological sequence database: https://bio-patsnap-com.libproxy1.nus.edu.sg. Act now to expedite your sequence search tasks.

图片包含 图示

描述已自动生成

Yasheng Pharmaceutical's Bcl-2/Bcl-xL dual-target inhibitor, APG-1252, releases its latest Phase 1b clinical trial data for the treatment of non-small cell lung cancer
Latest Hotspot
3 min read
Yasheng Pharmaceutical's Bcl-2/Bcl-xL dual-target inhibitor, APG-1252, releases its latest Phase 1b clinical trial data for the treatment of non-small cell lung cancer
26 October 2023
Yasheng Pharmaceutical presented updated clinical data for APG-1252 and Osimertinib to treat EGFR mutation lung cancer patients at the 2023 ESMO meeting on October 23, 2023.
Read →
Merck reports the use of LRRK2 inhibitor for Parkinson's treatment
Hot Spotlight
7 min read
Merck reports the use of LRRK2 inhibitor for Parkinson's treatment
26 October 2023
Merck Company published an article in the Journal of Medicinal Chemistry (JMC) on the 20th of this month, reporting on the discovery process of LRRK2 inhibitor MK1468.
Read →
BioNova Pharmaceuticals' oral Menin inhibitor BN104 has received Fast Track designation from the FDA for the treatment of acute myeloid leukemia
Latest Hotspot
3 min read
BioNova Pharmaceuticals' oral Menin inhibitor BN104 has received Fast Track designation from the FDA for the treatment of acute myeloid leukemia
26 October 2023
On October 24, 2023, BioNova Pharmaceuticals announced that the U.S. FDA has granted Fast Track Designation to its product BN104 for the treatment of relapsed/refractory acute leukemia.
Read →
Analysis on the Clinical Research Progress of Nuclear Factor
Analysis on the Clinical Research Progress of Nuclear Factor
26 October 2023
NF-κB is present in almost all animal cells and is a key transcription factor in various biological processes in the human body.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.